About Us

Committed to improving research and development productivity for organizations around the world through better science and technology.

Designed to Cure Webinars

Early discovery in biotherapeutics is undergoing massive changes as the need to source newer, innovative therapeutic candidates becomes ever greater. While new experimental methods, therapeutic pathways, and targets have opened many ways forward, traditional methods for capturing, visualizing, analyzing, and sharing data have proven unable to keep up with the pace of innovation. Early discovery teams need the ability to effectively collaborate to better identify new candidates, more quickly vet and ‘fail’ unsuitable ones, and efficiently utilize previous knowledge to pave the way forward to future success. Successfully adopting this approach can catalyze the R&D pipeline, leading to more impactful insights and widespread collaboration across the organization.

The Designed to Cure Industry Solution Experience transforms the discovery initiatives that drive the future of biotherapeutics organizations. It provides a novel, unified research environment by combining in silico modeling and simulation, experimental data capture and sharing, and workflow and process design.

Upcoming Webinars

Date Title and Speaker
February 5th, 2019
8am PT
11am ET
5pm CEST

Improving the Therapeutic Index of Antibody Drug Conjugates
Rakesh DIXIT, PhD, DABT Vice President, R&D; Global Head, Translational Sciences-Biologics Safety Assessment MedImmune

Antibody–drug conjugates (ADCs) generally refer to tumor antigen targeted antibodies incorporating cytotoxic anticancer drugs through highly stable linkers. Since the concept of a “magic bullet” for targeted drugs was coined, the approvals of brentuximab anti-CD33-ADC vedotin (in 2011) anti-HER2 ADC trastuzumab emtansine (in 2013) and Mylotarg CD33-Calicheamicin ADC (in 2017) have revolutionized the development of ADCs with over 250 clinical trials and more than 60 distinct ADC molecules currently in development. Despite this revolutionary growth, the low therapeutic index or limited safety window of ADCs has posed a major challenge in achieving the success in treatment of solid tumors.

Join our expert speaker for this complimentary webinar and learn about strategies for decreasing toxicities, increasing tumor cytotoxicity and overall improving the therapeutic index of ADCs.

Key learning objectives include:

  • Tumor intrinsic and warhead associated challenges in improving the TI
  • Why antibody characteristics are more important than first realized
  • Optimization of warhead potency
  • Pros and cons of site-specific conjugation and linkers
  • Impact of ADC disposition on TI
  • Dosing schedule and mitigation of toxicities
  • Translational medicine approaches to improve TI
 Register Now

Past Webinars

Title and Speaker

5 Ways Biopharma and Medical Device Manufacturers Can Accelerate Patient-Centric Innovation
Dr. Steve Levine, Sr. Director, Strategic Initiatives – Life Sciences Industry, Dassault Systèmes
Piere Frouin, Chief Executive Officer, BioSerenity

Biologics drugs, including monoclonal antibodies, are revolutionizing the treatment of human diseases. There are more than 60 antibodies that have been approved and over 300 biologic drugs at various stages of drug development. With transformational changes and the success of bioligics, there are increasingly newer challenges in development of biosimilars/bio-betters, immunomodulatory and antibody-drug conjugates (ADCs) biologics.

In this free and educational webinar, you’ll learn about:

  • The challenges and opportunities in development of biosimilars and bio-betters and the next generation of biologic drugs, including immunotherapy biologics and antibody drug conjugates.
  • Opportunities and challenges for early development, CMC, translational safety, PK-PD and efficacy of this next generation of biologics such as ADCs and immunotherapy biologics.
 Watch Now

Next Generation of Biosimilars Challenges and Opportunities
Rakesh Dixit, Ph.D., DABT, Vice President R&D, Global Head, Translational Sciences-Biologics Safety Assessment, Medimmune, a member of the AstraZeneca Group

Establishing and maintaining a competitive advantage in the life sciences industry means offering more innovative, patient-centric solutions that are not only safe and efficacious but are also convenient and truly address patients’ needs. Corporate growth and survival demand the ability to adapt to this changing landscape by optimizing an organization’s “innovation engine” without compromising time-to-market. In this webinar, you’ll get key insights into the development of patient-centric innovations.

Join us for this live webinar where we will discuss:

  • The new generation of cloud-based digital technologies that have lowered the cost of innovation while increasing reliability and robustness of solutions
  • How companies can leverage the Digital Twin concept to optimize the operation and maintenance of assets, systems and manufacturing processes in life sciences
  • Advancing biomedical engineering with new technologies designed to advance cardiovascular science through realistic simulation (the Living Heart Project)
 Watch Now

BIOVIA Science Council Webinar Augmenting Pharmaceutical Development with in silico Materials Design
Marc Meunier, Sr. Solution Scientist BIOVIA, Dassault Systèmes

A major challenge in determining the manufacturability of a candidate therapeutic is determining and optimizing the mechanisms behind its crystallization process, as different crystal shapes can have large impacts on the solubility and stability of the API. This pre-formulation phase is growing in prominence as a critical step in the pharmaceutical development process. It is now recognized that the decrease in productivity in the pharmaceutical industry is partly due to poor physical and material properties of the drug candidates.

Join us for this live webinar where we will discuss:

  • Why a more fundamental understanding of these properties leads to faster, more effective pharmaceutical development.
  • How in silico approaches can model and predict the stability of crystal polymorphs for an API.
  • Real world examples which demonstrate how in silico studies can impact pre-formulation pharmaceutical development.
 Watch Now

How to Manage your Growing Screening Assay Data
Thomas Blarre, Ph.D., Scientific Project Manager, Discngine

Most research and development laboratories already leverage todays screening technologies to quickly and consistently assess physical and biological properties of their molecules or assets. In recent years, technologies have improved, partnerships and business models evolved. As a result, the amount of data created by such screening techniques has grown in size and complexity, so the way scientists analyze, share or integrate their data has become challenging.

Join us for this webinar where we will discuss how BIOVIA Assay can support research scientists managing their plate-based assay data in an integrated solution.

Topics covered include:

  • Criteria for cloud-based or on premise implementations
  • A set of web-based, user-friendly applications
  • Ability to handle low- to high-throughput plate-based assays
  • Key aspects of plate inventory management
  • Data warehousing through central and essential raw data analysis
 Watch Now

Moving Toward Tailor-Made Molecules with AI-Driven Molecular Design and Optimization
Ton van Daelen, Ph.D., Sr. Product Director, BIOVIA, Dassault Systèmes

Enabling pharmaceutical, biotech, and agrochemical businesses to more efficiently produce safe, efficacious medicines and agents is key to improving R&D productivity and competitiveness. Recent advances in machine learning methods have shown the ability to generate and optimize compounds in-silico to meet a desired product profile.

Join us for this live webinar and learn how to:

  • Use machine learning to optimize target, anti-target, synthesizability, safety and toxicity profiles for molecules ready for synthesis and testing
  • Generate truly novel small molecule and biological entities de novo
  • Enhance machine learning models by updating models with proprietary data
  • Discover drugs and chemicals faster, and with an increased chance of meeting regulatory, business, and market requirements
 Watch Now

Accurate Antibody Molecular Modeling Enables Epitope Determination
Guy Georges, Roche and Hugues-Olivier Bertrand, Dassault Systèmes BIOVIA

During the past few years, modeling tools for antibody discovery and engineering have been developed, taking advantage of the structural knowledge existing in the protein database (PDB).

At Roche, a modeling tool is automatically producing high quality models at a very low computational cost. The tool uses an antibody structural database dissected in heavy and light chains, frameworks, and Complement Determining Regions (CDRs) segments that enables novel features in searching templates during modeling. An accurate prediction of the relative VH-VL orientation ensures the model quality. The VH-VL orientation prediction is also used to predict the CDR grafting success during humanization.

Watch this webinar to learn how to automate the generation of high-quality antibody structure models.

 Watch Now

Optimizing Your Plate Based Assay Workflows
Tim Moran, Product Marketing, Life Sciences R&D, Dassault Systèmes BIOVIA

Announcing the release of BIOVIA Assay and BIOVIA Sample for Assay for plate based assay analytics and related sample inventory, tracking and processing. Join us and learn how these integrated tools can improve your plate based screening. These workflow based software solutions guide scientists through various process in low to high throughput screening campaigns.

Design and manage your screening campaigns using BIOVIA Assay. The Oracle based platform covers analysis of cellular, molecular and high content screening. Key features include:

  • High throughput Dose Response Analysis
  • Convenient visual analytic capabilities
  • Fast and reproducible analysis of complex data-sets
  • Open to customization and integration with existing lab-equipment

BIOVIA Sample for Assay Key features include:

  • End-users are guided all along the various processes used in sample management operations
  • Piped jobs allow to chain complex operations with maximum traceability
  • Single platform for liquid and solid inventory management & tracking
  • Robotic equipment, barcode printers and balance integration
  • High level of performance: 100% of the code is executed by Oracle SQL core
 Watch Now

Leveraging Machine Learning for Decision Making in the Lab
Sean McGee, Product Marketing Manager – Life Sciences R&D, Dassault Systèmes BIOVIA

What Should I Do Next? How Democratized Machine Learning Supports Decision Making in Biopharmaceuticals R&D

Machine learning and Big Data analytics offer significant opportunities to improve biopharmaceuticals R&D, providing scientists with a new set of tools to analyze their data. These approaches can help scientists do more with less, building a stronger, data-driven foundation for decision making and guiding future research. However, traditional methods to apply these techniques required extensive custom coding, deep technical knowledge, and prohibitively large data sets to create an effective model.

Recent advances in machine learning and Big Data analytics have helped to mitigate these requirements, with tools designed specifically for biopharmaceuticals-focused data science. With these, scientists can develop custom models and algorithms much faster than before – no matter the size of their data sets – and can easily share them with their colleagues to ensure best practices are conserved across a research group.

This webinar will explore some use cases to show:

  • How machine learning and Big Data analytics can support data-driven decisions
  • How to leverage data-science pipelining tools to simplifying the model design process
  • Approaches for differently sized data sets
 Watch Now

How to Optimize Biologic Drug Development with the Power of Scientific Informatics
Dr. Hugues-Olivier Bertrand, Sr. Director of Life Science Research Pre-Sales, Sr. Fellow, BIOVIA Science Council, Dassault Systèmes BIOVIA

Dr. Anne Goupil-Lamy, Principal Field Application Scientist, Fellow, BIOVIA Science Council, Dassault Systèmes BIOVIA

Many organizations in the pharmaceutical and biopharmaceutical industries have increased their efforts in biotherapeutic drug development to remain competitive by shifting their activities away from small molecule toward biologics drug development.

The complex structure of Biologics, the nature of the interactions with their partners, require accurate modelling method to predict their physicochemical properties and ultimately accelerate innovation and bring better products to market faster.

Register for this webinar to learn how your organization can benefit from the BIOVIA Biologics design solution:

  • Sequence annotation and alignment
  • Identification of post-translational modification sites
  • Automatic antibody modelling cascade including full-length and bispecific antibodies
  • Epitope / Paratope detection
  • Affinity maturation
  • Prediction of antibody stability
  • Prediction of aggregation propensity
  • Biophysical property prediction for developability
 Watch Now

Challenges and Opportunities in Development of Biologic Drugs
Rakesh Dixit, PhD, DABT, VP of R&D, Global Head of Biologics Safety Assessment, MedImmune

Biologic drugs, including monoclonal antibodies are revolutionizing the treatment of human diseases. There are nearly 60 antibodies that are approved and over 300 or more biologic drugs are at various stages of drug development. This year alone, the FDA has approved 4 new antibodies in cancer treatment and more antibodies are likely to be approved.

With transformational changes in biologics, there are increasingly newer formats of new biologic drugs including bispecific antibodies, antibody drug conjugates and antibody-peptide fusion proteins. These formats are expanding the biologics world and new treatment modalities, however, these new formats have increased the challenges for drug development.

This presentation will discuss the challenges and opportunities in development of biosimilars and biobetters or the next generation of biologic drugs, including bispecific antibodies and antibody drug conjugates.

This will include a discussion on opportunities and challenges for early development, CMC, translational safety, PK-PD and efficacy of this next generation of biologics such as ADCs and bispecific drugs.

 Watch Now

In Silico Antibody Design Platform with Novel Protein Engineering Algorithms
Lisa Yan, Life Science Software Developer, Dassault Systèmes BIOVIA

Join us for this complimentary webinar where our technical expert will discuss new features and enhancements of BIOVIA Discovery Studio including new algorithms to use for predicting antibody stability and binding affinity upon mutation. Register now!

Presentation Abstract:

A general overview of the in silico antibody design platform in BIOVIA Discovery Studio will be presented, including annotation of antibody sequences, predicting post-translation modifications, generating 3D antibody Fv/FAB or full length structures from sequence, predicting antibody developability, humanization, and more. The presentation will then be focused on discussing the novel algorithms for predicting antibody stability and binding affinity upon mutation. Many of the predicted protein properties discussed in this presentation, including solubility, developability, stability and binding affinity can be calculated as function of solution pH by our method. Since the pH dependency of those properties are highly relevant for protein design, some of the validation results will be highlighted in the presentation.

 Watch Now

Out of Isolation: Embracing Collaborative Discovery
Alan S. Louie, Ph.D. Research Director / IDC Health Insights & Tim Moran Product Management Director / Dassault Systèmes BIOVIA


Discovery research in the life sciences has changed significantly since the time when a researcher would run a laboratory experiment at the lab bench, manually enter data into their paper lab notebook, and report results during the weekly group team meeting in a nearby conference room. Instruments generate much of today's data, electronic laboratory notebooks capture protocols, data, and insights, and research teams are spread around the world.

As we move forward, increasingly distributed, collaborative discovery research can benefit from technology tools that assist and empower today's researcher, providing them with resources to better achieve their potential, with a goal of accelerating discovery, advancing our knowledge, and helping to more quickly bring new solutions to society. In this short presentation, we will highlight the evolving discovery workspace and the opportunity to succeed in a rapidly changing life science ecosystem.

Key Learning Objectives:

  • The process of transitioning from an individual contributor to a team effort
  • Leveraging technology empowering operational excellence at the lab bench
  • Embracing discovery research as a part of the broader life science lifecycle
 Watch Now

A closer look at Dassault Systemès Designed to Cure Industry Solutions Experience
Tim Moran Director of Product Marketing, Biologics, Dassault Systemès BIOVIA & Adrian Stevens Senior Manager of Modeling & Simulations, Dassault Systemès BIOVIA

A closer look at Dassault Systemès Designed to Cure Industry Solutions Experience

Challenged by an expensive, slow and risky development process, today’s pharmaceutical manufacturers must find ways to better identify higher quality candidates while reducing cost and time to market. New drug development requires a mix of innovation and high variability that has to be documented and managed. This requires a flexible process and system that can accommodate changes on the fly and multiple iterations while capturing all the data created throughout the process.

Dassault Systèmes Designed to Cure Industry Solution Experience provides an integrated platform that delivers a data-driven innovation experience that reduce time to market through laboratory knowledge capture and predictive analytics.

Watch the webinar Getting to Market Faster with Higher Quality Novel Therapeutics here and you will:

  • Gain understanding of the key challenges of the pharmaceutical and biotech segments
  • See how the Designed to Cure Solution address can solve many of these problems
  • Observe one company’s experience of using capabilities of Designed to Cure and the value they derived from the solution

 Watch Now


Browse By: